PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp.

Biotechnology: Pharmaceutical Preparations

Health Care

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

IPO Year:

Exchange: NASDAQ

Website: phiopharma.com

Peers

$REKR

Recent Analyst Ratings for Phio Pharmaceuticals Corp.

Date	Price Target	Rating	Analyst
6/5/2025	$14.00	Buy	H.C. Wainwright

See more ratings

Phio Pharmaceuticals Corp. Press Releases

Fastest customizable press release news feed in the world

View All

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 5,663,182 shares of common stock of the Company originally issued in July 2024, December 2024, January 2025 and July 2025, having exercise prices between $2.00 and $5.45 per share. Warrants to purchase 60,000 shares of common stock will be exercised at their existing exercise price of $2.00 per share, warrant

11/3/25 1:40:00 PM ET

Phio Pharmaceuticals Corp.

Peers

Recent Analyst Ratings for Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp.

Peers

Recent Analyst Ratings for Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. Analyst Ratings

H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

Phio Pharmaceuticals Corp. SEC Filings

Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form S-8 filed by Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form DEFA14A filed by Phio Pharmaceuticals Corp.

SEC Form 424B3 filed by Phio Pharmaceuticals Corp.

SEC Form EFFECT filed by Phio Pharmaceuticals Corp.

SEC Form 10-Q filed by Phio Pharmaceuticals Corp.

SEC Form D filed by Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. Insider Purchases

Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)

Chairman, Pres & CEO Bitterman Robert J bought $7,446 worth of shares (4,200 units at $1.77), increasing direct ownership by 22% to 23,649 units (SEC Form 4)

Director Ferrara Robert L bought $4,550 worth of shares (2,500 units at $1.82), increasing direct ownership by 23% to 13,166 units (SEC Form 4)

President & CEO Bitterman Robert J bought $740 worth of shares (1,000 units at $0.74), increasing direct ownership by 5% to 20,990 units (SEC Form 4)

President & CEO Bitterman Robert J bought $750 worth of shares (1,000 units at $0.75), increasing direct ownership by 5% to 19,990 units (SEC Form 4)

Bitterman Robert J bought $2,275 worth of shares (2,500 units at $0.91), increasing direct ownership by 15% to 18,990 units (SEC Form 4)

Phio Pharmaceuticals Corp. Insider Trading

Amendment: Director Ferrara Robert L was granted 23,100 shares, increasing direct ownership by 147% to 38,766 units (SEC Form 4)

Director Deming David H was granted 14,000 shares (SEC Form 4)

Director Lockshin Curtis was granted 16,200 shares, increasing direct ownership by 688% to 18,555 units (SEC Form 4)

Director Freeman Jonathan E was granted 14,700 shares, increasing direct ownership by 1,085% to 16,055 units (SEC Form 4)

Director Ferrara Robert L was granted 23,000 shares, increasing direct ownership by 147% to 38,666 units (SEC Form 4)

VP, Finance and Administration Carson Lisa Cabott was granted 47,000 shares (SEC Form 4)

Director Bradford Patricia A was granted 18,800 shares, increasing direct ownership by 225% to 27,151 units (SEC Form 4)

Chairman, Pres. & CEO Bitterman Robert J covered exercise/tax liability with 4,111 shares and was granted 250,000 shares, increasing direct ownership by 963% to 271,421 units (SEC Form 4)

SEC Form 3 filed by new insider Carson Lisa Cabott

Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

Phio Pharmaceuticals Corp. Press Releases

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Phio Pharmaceuticals Corp. Leadership Updates

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces New Chief Financial Officer

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

SEC Form SC 13G filed

SEC Form SC 13G/A filed